Zacks: ITUS Corporation (NYSE:ANIX) Given $8.00 Average Target Price by Brokerages
Shares of ITUS Corporation (NYSE:ANIX) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus price objective of $8.00 for the company and are expecting that the company will post ($0.24) earnings per share for the current quarter, according to Zacks. Zacks has also given ITUS an industry rank of 83 out of 255 based on the ratings given to related companies.
Several analysts recently weighed in on ANIX shares. Zacks Investment Research upgraded ITUS from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a report on Wednesday, January 1st. B. Riley decreased their price objective on ITUS from $11.25 to $8.00 and set a “buy” rating for the company in a report on Monday, December 30th.
In related news, CEO Amit Kumar bought 20,000 shares of the business’s stock in a transaction on Tuesday, January 14th. The shares were bought at an average price of $2.99 per share, for a total transaction of $59,800.00. Following the completion of the purchase, the chief executive officer now directly owns 194,000 shares of the company’s stock, valued at $580,060. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Arnold M. Baskies bought 10,000 shares of the business’s stock in a transaction on Friday, January 17th. The stock was bought at an average price of $3.74 per share, for a total transaction of $37,400.00. Following the purchase, the director now directly owns 21,000 shares of the company’s stock, valued at $78,540. The disclosure for this purchase can be found here. Insiders purchased 37,400 shares of company stock valued at $121,620 over the last 90 days.
Anixa Biosciences, Inc engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body’s immunological response to the presence of a malignancy.
Featured Story: What is the FTSE 100 index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.